宁波优贝德产品网站Unibest
← Back to patent-cliff list

Ulixertinib

Tier C — Watch / trade

Ulixertinib

Vertex Pharmaceuticals Incorporated
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:ERK1, ERK2

Indications (approved):Multiple myeloma, Lymphoma, Non-Hodgkin lymphoma, Hepatoblastoma, Osteosarcoma, 横纹肌肉瘤, 横纹肌样瘤, Glioma

Regional status

US
Phase II
2013-03-01
EU
-
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 8 · Total yield 1.9 g
ULIXER-00135302-72-8ULIXER-00272652-33-6ULIXER-00340740-41-8ULIXER-004869886-85-1ULIXER-00573183-34-3ULIXER-006869886-86-2ULIXER-007869886-87-3ULIXER-008869886-88-4ULIXER-009869886-90-8ULIXER-010663611-73-2ULIXER-011659731-48-3Ulixertinib869886-67-9API · Ulixertinib
CodeCAS No.Intermediate
ULIXER-00135302-72-82,2,2-trichloro-1-(1H-pyrrol-2-yl)ethan-1-one
ULIXER-00272652-33-62,2,2-trichloro-1-(4-iodo-1H-pyrrol-2-yl)ethanone
ULIXER-00340740-41-8methyl 4-iodo-1H-pyrrole-2-carboxylate
ULIXER-004869886-85-1methyl 4-iodo-1-tosyl-1H-pyrrole-2-carboxylate
ULIXER-00573183-34-3Available4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)
ULIXER-006869886-86-2methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-pyrrole-2-carboxylate
ULIXER-007869886-87-35-chloro-4-iodo-N-isopropylpyridin-2-amine
ULIXER-008869886-88-4methyl 4-(5-chloro-2-(isopropylamino)pyridin-4-yl)-1-tosyl-1H-pyrrole-2-carboxylate
ULIXER-009869886-90-84-(5-chloro-2-(isopropylamino)pyridin-4-yl)-1H-pyrrole-2-carboxylic acid
ULIXER-010663611-73-2(S)-2-amino-2-(3-chlorophenyl)ethanol
ULIXER-011659731-48-35-chloro-2-fluoro-4-iodopyridine
Ulixertinib869886-67-9-

Frequently asked questions

What are the approved indications of Ulixertinib?

Approved indications include: Multiple myeloma, Lymphoma, Non-Hodgkin lymphoma, Hepatoblastoma, Osteosarcoma, 横纹肌肉瘤, 横纹肌样瘤, Glioma.

When does the Ulixertinib patent expire?

No public expiry year is available for Ulixertinib yet; this page updates once verified.

How many synthesis routes are recorded for Ulixertinib?

1 synthesis routes are recorded; the shortest is 8 steps with 1.9 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Ulixertinib intermediates?

1 intermediate CAS of Ulixertinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Ulixertinib intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-13